Literature DB >> 15838379

Mature dendritic cells induce tumor-specific type 1 regulatory T cells.

Andreas Lundqvist1, Andreas Palmborg, Maxim Pavlenko, Jelena Levitskaya, Pavel Pisa.   

Abstract

The aim of this study was to compare the tumor antigen-specific T-cell repertoire generated by transduced, human dendritic cells (DCs). The transductions were three commonly used antigen delivery procedures: adenovirus (AdV) infection, RNA electroporation, and liposome-mediated protein transfection. The DCs in each experimental group were transfected with similar efficacy and matured using TNF-alpha, anti-CD40, or lipopolysaccharide. Regardless of the gene transfer method or the maturation stimuli used, the DCs were indistinguishable with regard to surface phenotype and allostimulatory capacity. With the exception of the Adv transduced group, the T cells generated were tumor antigen specific, as characterized by high IFN-gamma production. The T cells generated upon stimulation with DCs subjected to AdV infection, and subsequently treated with TNF-alpha, exhibited tumor antigen specificity, but accompanied by reduced proliferation and IFNgamma production and increased IL-10 production. Moreover, these T cells exerted a suppressive effect on both autologous and allogeneic lymphocytes resembling type 1 regulatory T cells (Tr1). The authors show that mature DCs may induce tumor antigen-specific Tr1 cells by the appearance of high IL-10 and low IL-12. Similar results were also obtained with AdV-infected and TNF-matured DCs regardless of the transgene used. This work supports the conclusion that it can no longer be assumed that mature DCs induce only antitumor reactive T cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15838379     DOI: 10.1097/01.cji.0000158854.15664.c2

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  7 in total

1.  The cross-regulatory relationship between human dendritic and regulatory T cells and its role in type 1 diabetes mellitus.

Authors:  Hsuen-Wen Chang; Yen-Hung Chow; Pele Chong; Charles Sia
Journal:  Rev Diabet Stud       Date:  2007-08-10

2.  Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors.

Authors:  Alexander Pedroza-Gonzalez; Guoying Zhou; Ernesto Vargas-Mendez; Patrick Pc Boor; Shanta Mancham; Cornelis Verhoef; Wojciech G Polak; Dirk Grünhagen; Qiuwei Pan; Harry LA Janssen; Gina S Garcia-Romo; Katharina Biermann; Eric Ttl Tjwa; Jan Nm IJzermans; Jaap Kwekkeboom; Dave Sprengers
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

3.  A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors.

Authors:  Andrew J Lepisto; Arthur J Moser; Herbert Zeh; Kenneth Lee; David Bartlett; John R McKolanis; Brian A Geller; Amy Schmotzer; Douglas P Potter; Theresa Whiteside; Olivera J Finn; Ramesh K Ramanathan
Journal:  Cancer Ther       Date:  2008

4.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

Review 5.  Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.

Authors:  Alti Dayakar; Sambamurthy Chandrasekaran; Suresh V Kuchipudi; Suresh K Kalangi
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

Review 6.  Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer.

Authors:  Isabella Lurje; Linda Hammerich; Frank Tacke
Journal:  Int J Mol Sci       Date:  2020-10-06       Impact factor: 5.923

7.  Immunosuppression induced by immature dendritic cells is mediated by TGF-beta/IL-10 double-positive CD4+ regulatory T cells.

Authors:  N Cools; V F I Van Tendeloo; E L J M Smits; M Lenjou; G Nijs; D R Van Bockstaele; Z N Berneman; P Ponsaerts
Journal:  J Cell Mol Med       Date:  2008-04       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.